Joel Beatty

Esperion Therapeutics Inc (NASDAQ: ESPR) is finishing research on its bemepedoic acid for lipid management, and while the Street expects success, the drug’s potential is weighted by a dearth of interested buyers. The Rating Citi analyst Joel Beatty downgraded Esperion to Neutral, but raised...

Novavax, Inc. (NASDAQ: NVAX), a small-cap clinical-stage vaccine company that focuses on therapies for both known and newly emerging diseases, has lost some support from a Wall Street analyst. The Analyst Citi's Joel Beatty downgraded Novavax's stock from Buy to Neutral. The Thesis...

Analysts at Citi turned bullish on Novavax, Inc. (NASDAQ: NVAX), a small-cap clinical-stage vaccine company. The firm's Joel Beatty upgrades Novavax's stock rating from Neutral to Buy with a price target boosted from $1.10 to $1.60. Novavax's phase 1 and phase 2 data for its flu vaccine called...

It’s hard to find a silver lining following news that sends a stock crashing 84.5 percent in one day. However, following devastating news that the Phase III RESOLVE trial of its RSV vaccine failed to deliver the desired results, Novavax, Inc. (NASDAQ: NVAX) shareholders are looking for any...

Following disappointing Phase 3 results for the RSV vaccine in older adults, Novavax, Inc. (NASDAQ: NVAX) reported mixed results for a Phase 2 trial of the vaccine on older adults who were reimmunized. Citi’s Joel Beatty downgraded the rating on the company from Buy to Neutral, while...

Raptor Pharmaceutical Corp. (NASDAQ: RPTP) reported its 2Q16 revenue ahead of expectations. Citi’s Joel Beatty downgraded the rating on the company from Buy to Neutral, citing elevated investor expectations around revenue. The price target has been raised from $6 to $8. Results And...

Esperion Therapeutics Inc (NASDAQ: ESPR) announced that the FDA had not agreed to LDL as an approvable surrogate endpoint for the company’s cholesterol agent bempedoic acid. Citi’s Joel Beatty maintained a Buy rating on the company, while reducing the price target from $36 to $22. The...

Morgan Stanley’s Matthew Harrison initiated coverage of Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with an Overweight rating and price target of $22, while Citi’s Joel Beatty also initiated coverage of the company with a Buy rating and price target of $24. Major Value Driver Both...

Citi's Joel Beatty downgraded the rating on PTC Therapeutics, Inc. (NASDAQ: PTCT) from Buy to Neutral, while lowering the price target from $90 to $13. The downgrade follows the company's announcement on February 23 that the FDA has refused to review the Translarna application in the...

The Medicines Company (NASDAQ: MDCO)'s blood-clot prevention drug will serve as a last-line treatment with limited sales, an analyst said Thursday. A Food and Drug Administration advisory panel on Wednesday recommended the company's cangrelor as a treatment for certain heart-surgery patents. But...